


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1. (Currently Amended) A compound of Formula I



or a pharmaceutically acceptable salt of said compound; wherein

R₁ is a) ~~-(C₁-C₆)alkyl optionally substituted with -CF₃, b) -C≡C-CH₃, or c) -C≡C-Cl, d) -C≡C-CF₃, e) b)~~ -CH₂O(C₁-C₄)alkyl optionally substituted with -CF₃ or ~~f) -CF₃~~;

R₂ is a) -(C₁-C₅)alkyl, b) -(C₂-C₅)alkenyl or c) -phenyl optionally substituted with one of the following: -OH, -NR₉-C(O)-(C₂-C₄)alkyl, -CN, -Z-het, -O-(C₁-C₃)alkyl-C(O)-NR₉R₁₀, -NR₉-Z-C(O)-NR₉R₁₀, -Z-NR₉-SO₂-R₁₀, -NR₉-SO₂-het, -O-C(O)-(C₁-C₄)alkyl or -O-SO₂-(C₁-C₄)alkyl;

Z for each occurrence is independently -(C₀-C₄)alkyl;

R₃ is a) -hydrogen, b) -(C₁-C₆)alkyl optionally substituted with one to three halo, c) -(C₂-C₆)alkenyl or d) -(C₂-C₆)alkynyl optionally substituted with one to three halo;

R₄ is a) hydrogen or b) -(C₂-C₅)alkyl-NR₅R₆;

R₅ and R₆ are each independently ~~a) hydrogen or b)~~ -(C₁-C₃)alkyl;

het is an optionally substituted 5-, 6- or 7-membered saturated, partially saturated or unsaturated heterocyclic ring containing from 1 to 3 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur; and including any bicyclic group in which any of the above heterocyclic rings is fused to a benzene ring or another heterocyclic ring; and optionally substituted with one to four R₇; provided that het is other than pyridinyl, imidazolyl or tetrazolyl;

R₇ is a) -(C₁-C₆)alkyl optionally substituted with one to three R₈, b) -Z-NR₉R₁₀ or c) -Z-C(O)-NR₉R₁₀;

R₈ for each occurrence is independently a) halo, b) -OH, c) oxo or d) -O(C₁-C₆)alkyl;

R₉ and R₁₀ for each occurrence are independently a) -H or b) -(C₁-C₃)alkyl;

or R₉ and R₁₀ are taken together with N to form het;


provided that:

1) when R₁ is -C≡C-CH₃, R₂ is phenyl and R₃ is hydrogen, then R₄ is other than -(CH₂)₂-N(CH₃)₂, or -(CH₂)₃-N(CH₃)₂;

2) when R₁ is -C≡C-CH₃, R₂ is propyl and R₃ is hydrogen, then R₄ is other than -(CH₂)₂-N(CH₃)₂; and

3) when R₁ is -C≡C-CH₃, R₂ is butyl and R₃ is hydrogen, then R₄ is other than -(CH₂)₂-N(CH₃)₂.

2. (Currently Amended) A compound of claim 1 of Formula II



II

or a pharmaceutically acceptable salt of said compound; wherein

R₁ is a) ~~-(C₁-C₆)alkyl optionally substituted with -CF₃, b) -C≡C-CH₃, c) -C≡C-CH₃-CF₃, d) -CF₃, or e) -C≡C-CH₃ or b) -CH₂O(C₂-C₄)alkyl.~~

3. (Currently Amended) A compound of claim 2 wherein R₁ is a) ~~-CH₂CH₂CH₃, b) -C≡C-CH₃ or c) -CF₃.~~

4. (Original) A compound of claim 3 wherein

R₃ is a) hydrogen, b) methyl, c) ethyl, d) propyl or e) isopropyl;

R₄ is -(C₂-C₃)alkyl-NR₅R₆;

R₅ and R₆ are each independently a) methyl, b) ethyl, c) propyl or d) isopropyl.

5. (Original) A compound of claim 4 wherein

R₃ is a) methyl, b) ethyl, c) propyl or d) isopropyl;

R₄ is -(C₂-C₃)alkyl-NR₅R₆;

R₅ and R₆ are each independently a) methyl, b) ethyl, c) propyl or d) isopropyl.

6. (Original) A compound of claim 5 wherein

R₃ is a) methyl or b) ethyl;

R₄ is -(C₂-C₃)alkyl-NR₅R₆;

R₅ and R₆ are each methyl.

7-11. (Canceled)

12. (Currently Amended) A compound of claim 1 wherein

R₁ is a) ~~-CH₂CH₂CH₃~~, b) -C≡C-CH₃ or c) ~~-CF₃~~;

R₂ is a) -(C₁-C₅)alkyl or b) -(C₂-C₅)alkenyl;

R₃ is a) hydrogen, b) methyl, c) ethyl, d) propyl or e) isopropyl;

R₄ is -(C₂-C₃)alkyl-NR₅R₆;

R₅ and R₆ are each independently a) methyl, b) ethyl, c) propyl or d) isopropyl.

13. (Original) A compound of claim 12 wherein

R₂ is a) methyl, b) ethyl, c) propyl, d) ethenyl, e) propenyl or f) butenyl;

R₃ is a) hydrogen, b) methyl or c) ethyl,

R₅ and R₆ are each independently a) methyl or b) ethyl.

14-17. (Canceled)

18. (Previously Presented) A compound of claim 1 wherein in Formula I R₂ is ethenyl or ethyl.

19-23. (Canceled)

24. (Original) A compound of claim 13 selected from the group consisting of:

carbamic acid, (3-dimethylaminopropyl)methyl-, (4b*S*, 7*R*, 8a*R*)-4b,5,6,7,8,8a,9,10-octahydro-4b-ethyl-7-hydroxy-7-prop-1-ynyl-phenanthren-2-yl ester;

carbamic acid, (2-dimethylaminoethyl)methyl-, (4b*S*, 7*R*, 8a*R*)-4b,5,6,7,8,8a,9,10-octahydro-4b-ethyl-7-hydroxy-7-prop-1-ynyl-phenanthren-2-yl ester;

carbamic acid, (2-dimethylaminoethyl)ethyl-, (4b*S*, 7*R*, 8a*R*)-4b,5,6,7,8,8a,9,10-octahydro-4b-ethyl-7-hydroxy-7-prop-1-ynyl-phenanthren-2-yl ester; and

carbamic acid, (2-dimethylaminoethyl)-, (4b*S*, 7*R*, 8a*R*)-4b,5,6,7,8,8a,9,10-octahydro-4b-ethyl-7-hydroxy-7-prop-1-ynyl-phenanthren-2-yl ester.

25-26. (Canceled)

27. (Previously Presented) A method for the treatment of a glucocorticoid receptor-mediated disease or condition which is selected from the group consisting of obesity, diabetes, depression, anxiety and neurodegeneration in a mammal, which comprises administering to the mammal a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt of said compound.

28. (Canceled)

29. (Previously Presented) The method of claim 27 wherein the condition is obesity.

30-41. (Canceled)